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Polyglutamine expansion in huntingtin is the under-
lying mutation leading to neurodegeneration in Hunt-
ington disease. This mutation influences the interaction
of huntingtin with different proteins, including hun-
tingtin-interacting protein 1 (HIP1), in which affinity to
bind to mutant huntingtin is profoundly reduced. Here
we demonstrate that HIP1 colocalizes with markers of
clathrin-mediated endocytosis in neuronal cells and is
highly enriched on clathrin-coated vesicles (CCVs) pu-
rified from brain homogenates. HIP1 binds to the clath-
rin adaptor protein 2 (AP2) and the terminal domain of
the clathrin heavy chain, predominantly through a
small fragment encompassing amino acids 276–335. This
region, which contains consensus clathrin- and AP2-
binding sites, functions in conjunction with the coiled-
coil domain to target HIP1 to CCVs. Expression of vari-
ous HIP1 fragments leads to a potent block of clathrin-
mediated endocytosis. Our findings demonstrate that
HIP1 is a novel component of the endocytic machinery.
Huntingtin-interacting protein 1 (HIP1)1 was identified
through its binding to the N-terminal domain of huntingtin, a
region containing a polymorphic stretch of glutamine residues
(1, 2). When the number of glutamines expands beyond 35,
individuals who express the mutated protein develop Hunting-
ton disease, which is characterized by selective neuronal de-
generation and is manifest clinically by chorea and intellectual
decline. Binding of HIP1 to huntingtin is reduced dramatically
following polyglutamine expansion (1), may contribute to the
initiation and progression of the disease.
HIP1 belongs to a family of proteins consisting of HIP1 and
HIP12/(HIP1R) (3). HIP12 was identified based on its homol-
ogy with HIP1, but unlike HIP1, it does not bind to huntingtin
(4). In addition to a central coiled-coil domain, HIP1 and HIP12
contain an ENTH (epsin N-terminal homology) domain. The
ENTH domain is thought to function in clathrin-mediated en-
docytosis through binding to phosphatidylinositol 4,5-bisphos-
phate (PtdIns(4,5)P2)-containing membranes (5–7). ENTH do-
mains are found in multiple endocytic proteins including epsin
1 and 2, adaptor protein 180 (AP180) and its homologue, clath-
rin assembly lymphoid myeloid leukemia protein (CALM). In-
terestingly, each of these proteins also bind to clathrin (8–11).
In the case of epsin 1 and 2, clathrin binding is to the N-
terminal domain of the clathrin heavy chain (CHC) and is
mediated in part via a type-I clathrin-binding sequence, also
called the clathrin box (12). Proteins that bind both
PtdIns(4,5)P2 and clathrin are thought to promote the linkage
of clathrin triskelia to the lipid bilayer (7). Whether HIP1 or
HIP12 binds to clathrin is currently unknown. However, HIP12
colocalizes with markers of receptor-mediated endocytosis in
mammalian cells and cofractionates with CCVs (3). Moreover,
mutations in the yeast HIP1/HIP12 homologue Sla2p result in
a temperature-sensitive defect in clathrin-mediated endocyto-
sis (13–17).
Here, we report that HIP1 colocalizes with endocytic mark-
ers, is enriched on CCVs, and binds directly to clathrin and
AP2. Moreover, expression of various HIP1 fragments causes a
potent block of clathrin-mediated endocytosis, directly impli-
cating HIP1 in endocytic function. These data suggest that
neurological defects seen in Huntington disease may be related
to abnormalities in endocytosis.
EXPERIMENTAL PROCEDURES
Antibodies—Rabbit polyclonal anti-HIP1 (HIP1FP) antibody was de-
scribed previously (4). The mouse monoclonal anti-HIP1 antibody (mAb
HIP1-9) was generated by immunization of Balb/C mice with a GST
fusion protein encoding the huntingtin-interacting domain of human
HIP1 (1). Hybridomas were generated and cloned and HIP1 mAbs were
selected by enzyme-linked immunosorbent assay with purified HIP1.
Positive hybridomas were further characterized by Western blot, and
mAb HIP1-9 was found to interact specifically with human and mouse
HIP1. Mouse mAbs recognizing -adaptin, CHC, or Rab5 were from
Transduction Laboratories, mouse mAb directed against CHC was from
Affinity Bioreagents Inc., and rabbit polyclonal anti--adaptin was
from Santa Cruz. Mouse mAbs directed against the Flag- and tetra-His
epitopes were from Sigma and Qiagen, respectively.
DNA Constructs—HIP1 mammalian expression constructs were gen-
erated with HIP1 splice variant 2 (4), which encodes the 1003-amino
acid isoform of HIP1. HIP1 cDNA sequences were cloned into the
mammalian expression vector pCI (Promega) and tagged at their re-
spective C termini with the following cDNA sequence: 5-GGAGGTG-
GAGACTACAAGGACGACGATGACAAGTAG-3. This cDNA encodes a
linker of three glycines, the Flag tag, and a stop codon. The following
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HIP1-GST fusion proteins were created by polymerase chain reaction
amplification from full-length HIP1 cDNA with subsequent cloning into
the appropriate pGEX vectors (Amersham Pharmacia Biotech): GST-
HIP1-(219–616), GST-HIP1-(276–335). For the His6-tagged terminal
domain (TD) of clathrin, a GST construct encoding the 579 amino acids
of the CHC in pGEX-2T (generous gift of James Keen, Thomas Jefferson
University, Philadelphia) was digested with BamHI and EcoRI, and the
resulting insert was subcloned into the pTrcHisA (Invitrogen) at the
same sites. All expression constructs were verified by DNA sequencing.
Immunofluorescence—Cells were washed in phosphate-buffered sa-
line (PBS; 20 mM NaH2PO4, 0.9% NaCl, pH 7.4), fixed in 4% paraform-
aldehyde in PBS, and permeabilized in 0.3% Triton X-100, 1%
paraformaldehyde. Nonspecific binding sites were blocked by incuba-
tion with 3% normal goat serum in PBS. For double immunofluores-
cence, HIP1 polyclonal antibody was incubated in 2% normal goat
serum in PBS at 4 °C overnight followed by incubation with mAbs
directed against endocytic markers for 2 h at room temperature. Cells
were washed extensively in PBS between each incubation. Cells were
then incubated with secondary antibodies, washed, mounted, and ob-
served by confocal microscopy.
Transferrin Uptake Assays—COS-7 cells plated on poly-L-lysine-
coated coverslips were transfected, cultured for 24 h, and serum-
starved overnight. The cells were then incubated with Cy3-conjugated
human transferrin (25 g/ml) for 20 min at 37 °C, washed three times
with PBS, and fixed with 3.5% paraformaldehyde in PBS. Following
fixation, coverslips were processed for immunostaining with a mono-
clonal anti-Flag antibody as above.
Purification of CCVs—CCVs from rat brain were purified as de-
scribed (18). A short version of the purification was adapted for trans-
fected cells. Specifically, cells were homogenized in buffer A (0.1 M MES,
pH 6.5, 1 mM EGTA, 0.5 mM MgCl2, 0.83 mM benzamidine, 0.23 mM
phenylmethylsulfonyl fluoride, 0.5 g/ml aprotinin, and 0.5 g/ml leu-
peptin) using a glass-Teflon homogenizer (10 strokes, 1500 rpm). The
homogenate (H) was centrifuged at 17,800  gmax for 20 min, and the
supernatant (S1) was collected and centrifuged at 56,100 gmax for 1 h.
The pellet (P2) was resuspended in buffer A using a glass-Teflon ho-
mogenizer (3 strokes, 1500 rpm) followed by dispersion through a 25-
gauge needle. The resuspended pellet was loaded on top of a solution
containing 8% sucrose in buffer A made in D2O and centrifuged for 2 h
at 115,800  gmax. The pellet containing the CCVs was collected.
Pull-down and Binding Assays—Adult rat brains were homogenized
in buffer B (10 mM HEPES, pH 7.4, 0.83 mM benzamidine, 0.23 mM
phenylmethylsulfonyl fluoride, 0.5 g/ml aprotinin, and 0.5 g/ml leu-
peptin), and a cytosolic fraction was generated by centrifugation at
205,000  gmax for 30 min at 4 °C. Triton X-100 was added to the
cytosolic fraction (2 mg) to a 1% final concentration, and the samples
were incubated overnight at 4 °C with GST fusion proteins precoupled
to glutathione-Sepharose beads. After incubation, samples were
washed three times in buffer B containing 1% Triton X-100. In other
cases, a His6-tagged fusion protein encoding the clathrin TD (25 g) was
incubated overnight at 4 °C in buffer B with the various GST fusion
proteins precoupled to glutathione-Sepharose beads. After incubation,
samples were washed three times in buffer B. For all assays, specifically
bound proteins were eluted in SDS-PAGE sample buffer and processed
for Western blot analysis.
Immunoprecipitation Analyses—Forty-eight hours following trans-
fection, 293T cells were washed in PBS, scraped in buffer B, and
sonicated, and Triton X-100 was added to a 1% final concentration. The
lysates were rocked for 30 min at 4 °C and then centrifuged at
245,000  gmax for 15 min. Supernatants were incubated overnight at
4 °C with anti-Flag antibody precoupled to protein G-Sepharose. After
incubation, samples were washed three times in buffer B containing 1%
Triton X-100. Bound proteins were eluted in SDS-PAGE sample buffer
and processed for Western blot analysis.
RESULTS AND DISCUSSION
HIP1 Is Localized to Endocytic Vesicles—Several lines of
evidence suggest a potential role for HIP1 in clathrin-mediated
endocytosis. We thus examined whether endogenous HIP1 co-
localizes with endocytic markers. As HIP1 is most abundant in
brain (1, 2), these studies were performed in the neuronal
precursor cell line NT2. HIP1 demonstrates punctate staining
that is closely colocalized with AP2 (Fig. 1A). Moreover, HIP1
colocalizes with the CHC but shows only partial overlap with
the early endosomal marker Rab5. Similar results were ob-
tained in primary striatal neurons (data not shown). These
data suggest that HIP1 is closely associated with endocytic
vesicles. To explore this possibility further, we purified CCVs
from rat brain extracts. The coats were then stripped from the
vesicles using 0.5 M Tris, pH 9.0. HIP1 was enriched in both the
coat fraction and the stripped vesicle fraction when compared
with homogenates, with the highest degree of enrichment de-
tected in the coats (Fig. 1B). The enrichment of HIP1 in the
clathrin coats was comparable with that of clathrin and AP2
(Fig. 1B). In contrast, other accessory proteins like amphiphy-
sin, epsin, and Eps15 are far less enriched on CCVs (19, 20).
Thus, HIP1 is a major component of CCVs.
Two Regions in HIP1 Are Necessary for Endocytic Target-
ing—To define the domains necessary for the localization of
HIP1, we prepared CCVs from mammalian cells transfected
with various HIP1 expression constructs (Fig. 2A). All con-
structs were verified by Western blot following transfection to
demonstrate that the expressed fragments were of the correct
size (Fig. 2B). We used a modified version of the CCV purifica-
tion (see “Experimental Procedures”). However, this procedure
gives a comparable enrichment of clathrin as does the classical
protocol (Fig. 2C). Full-length HIP1 was enriched in the CCV
fraction (Fig. 2C). The relative enrichment of HIP1 in the CCV
fraction compared with the homogenate was not as great as
that seen for the endogenous protein (Fig. 1B), probably be-
cause HIP1 is overexpressed in the cells. In contrast to full-
length HIP1, HIP1-cc, lacking the coiled-coil region, corre-
FIG. 1. HIP1 colocalizes with markers of endocytosis and is
enriched in CCVs. A, localization of HIP1 (green) with -adaptin,
clathrin, and Rab5 (red) was analyzed in neuronal NT2 cells. Overlays
of the images are shown in the right panels. Bars, 10 m. B, purification
of CCVs was performed by subcellular fractionation of E18 rat brain
homogenates. Aliquots of 100 g of homogenate (fraction H), pellet 1
(P1), pellet 2 (P2), supernatant 2 (S2), pellet obtained after sucrose
gradient centrifugation (SGp), supernatant obtained after sucrose
gradient centrifugation (SGs), coats, and vesicles were analyzed on
SDS-PAGE and immunoblotted with anti-HIP1-9, anti-CHC, and
anti--adaptin.
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sponding to amino acids 336–610, and HIP1-N-term, lacking
the N-terminal portion, corresponding to amino acids 1–335,
are not enriched in the CCV fraction compared with the homog-
enate (Fig. 2C). These results suggest that the coiled-coil region
and the N-terminal portion of HIP1 contain information nec-
essary for the targeting of HIP1 to CCVs. These domains also
appear sufficient for targeting as the construct HIP1-(155–610)
is enriched in the CCV fraction (Fig. 2C). As a negative control,
we used a construct encoding the talin domain of HIP1 (Fig.
2A). This protein was not present in the CCVs (Fig. 2C).
We next examined the constructs for colocalization with AP2.
Transfected full-length HIP1 showed extensive colocalization
with AP2 (Fig. 2D, top row). In contrast, deletion of either the
N-terminal domain or the coiled-coil domain abolished AP2
colocalization (Fig. 2D, two middle rows). Expression of HIP1-
(155–610) containing the coiled-coil region and upstream se-
quences resulted in extensive colocalization of HIP1 with AP2
(Fig. 2D, bottom row). These data indicate that sequences im-
portant for colocalization of HIP1 and AP2 are contained be-
tween amino acids 155–610.
FIG. 2. HIP1 targeting to CCVs. A, domain model of full-length HIP1 and HIP1 mutants (amino acid position numbers are indicated above the
constructs). B, expression of each construct (1–5) was analyzed by Western blot and compared with non-transfected cells () using an anti-Flag
antibody. C, 293T cells were transfected with various constructs of HIP1 and CCVs were purified as described under “Experimental Procedures.”
Aliquots of various fractions from the purification (100 g) were analyzed by Western blot with anti-CHC antibody or anti-Flag antibody. D,
expression of transfected HIP1 and various HIP1 mutants (red) was visualized using an anti-Flag antibody following transfection in HeLa cells.
Expression of AP2 is shown in green. Overlays of the images are shown on the right panels. Bars, 10 m.
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Hip1 Binds to AP2 and the Clathrin Terminal Domain—
Analysis of HIP1 revealed the amino acid sequence 298LMDMD
(Fig. 3A). Related sequences are found in a variety of endocytic
proteins and are responsible for mediating interactions with
the clathrin TD. HIP1 also contains a DPF motif (amino acids
324–326), a signature for AP2 binding (Fig. 3B). To address the
potential clathrin and AP2 binding properties of HIP1, we
designed two GST fusion proteins encompassing amino acids
219–616 and 276–335 (Fig. 3B). Both fusion proteins bound
strongly to clathrin and AP2 from soluble rat brain extracts
(Fig. 3C). Clathrin binding was significantly greater to HIP1-
(219–616) than to HIP1-(276–335) (binding ratio  1.22 
0.06; mean  S.E., n  6). In contrast, AP2 demonstrated
consistently less binding to HIP1-(219–616) than to HIP1-
(276–335) (binding ratio  0.66  0.09; mean  S.E., n  7).
The significantly different ratios for clathrin and AP2 binding
(p  0.001; t test) suggest that the binding of AP2 is direct and
does not result from an indirect pull-down mediated through
clathrin. Moreover, the increased binding of clathrin to HIP1-
(219–616) versus HIP1-(276–335) suggests that a second bind-
ing site for clathrin exists in HIP1, likely in the coiled-coil
region (amino acids 336–610). The HIP1-GST fusion proteins
also bind to purified His6-tagged clathrin TD demonstrating
that clathrin/HIP1 interaction is direct (Fig. 3C, middle panel).
Binding of the TD to HIP1-(219–616) and HIP1-(276–335) was
equivalent, suggesting that the second clathrin-binding site
located in the coiled-coil region does not bind clathrin through
the TD. In addition, we were able to immunoprecipitate the
clathrin adaptor AP2 with full-length HIP1 in transfected cells
(Fig. 3D).
FIG. 3. HIP1 binds clathrin and
AP2. A, sequence alignment of HIP1 with
various clathrin box-containing proteins.
B, schematic presentation of Flag-tagged
full-length HIP1 and sequences present
in different HIP1-GST fusion proteins. C,
soluble proteins from brain extracts or
purified His6-tagged clathrin TD fusion
protein were affinity-purified with equal
amounts of GST fusion proteins encoding
domains of HIP1 bound to glutathione-
Sepharose beads. Proteins specifically
bound to the beads were analyzed by
Western blotting with anti-CHC, anti-tet-
ra-His, and anti--adaptin antibodies as
indicated. D, 293T cells were transfected
with Flag-tagged full-length HIP1 and
processed in parallel with nontransfected
cells (). Proteins were extracted and im-
munoprecipitated with anti-Flag anti-
body. Immunoprecipitated proteins were
analyzed by Western blotting with anti--
adaptin and anti-Flag antibodies.
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The sequence that represents the clathrin box in HIP1,
298LMDMD, corresponds well with the previously described
consensus sequence (21–23). The clathrin box and the DPF are
arranged in tandem in HIP1 just upstream of the coiled-coil
domain. Several other proteins contain a similar arrangement
including amphiphysin I (24), epsins (12), and arrestins (25). A
tandem arrangement of clathrin- and AP2-binding sites is pre-
dicted to stabilize clathrin/adaptor interactions because the
interaction of the clathrin TD with the AP2 complex is rather
weak (12).
HIP1 Functions in Endocytosis—To directly assess whether
HIP1 functions in endocytosis, we performed transferrin up-
take in COS-7 cells transfected with the various constructs
described in Fig. 4A. We observed efficient transferrin uptake
in cells transfected with either full-length HIP1 (Fig. 4B, pan-
els i and v) or the isolated coiled-coil region (panels ii and vi).
Interestingly, expression of the construct HIP1-(155–610) or
HIP1-(155–335) strongly reduced transferrin uptake (Fig. 4B,
panels iii, vii, iv, and viii). Fig. 4C is a graph of the quantified
results from six separate experiments. We conclude that the
region upstream of the coiled-coil domain of HIP1 containing
the AP2- and the clathrin TD-binding sites is a potent inhibitor
of endocytosis.
Many proteins involved in clathrin-mediated endocytosis
contain specialized domains mediating protein-protein or pro-
tein-lipid interactions (26, 27). We have now identified HIP1 as
a novel component of clathrin-coated pits and vesicles. HIP1
binds directly to clathrin and AP2, and expression of a short
fragment of HIP1, encompassing binding sites for both pro-
teins, causes a potent block of transferrin uptake. The binding
of HIP1 to clathrin and AP2 occurs through a clathrin box and
a DPF consensus AP2-binding site, respectively. In addition,
HIP1 contains an ENTH domain, described in other proteins to
bind to PtdIns(4,5)P2-containing membranes (5–7). It is thus
tempting to speculate that HIP1 functions to link components
of the clathrin coat to PtdIns(4,5)P2-containing endocytic
vesicles.
HIP1 is enriched on CCVs to the same extent as clathrin,
AP2, and AP180. AP180 cooperatively assembles clathrin with
AP2 (28). AP180 binds to the TD of clathrin and the -append-
age of AP2 through its clathrin assembly domain. This domain
is characterized by multiple copies of a conserved motif, DLL
(29). One such motif is found in the coiled-coil region of HIP1 at
amino acid position 450. However, it remains to be determined
whether HIP1 can confer clathrin-assembly activity.
The identification of the neuronal protein HIP1 as a novel
component of the endocytic machinery leads us to suggest that
HIP1 may function in synaptic vesicle endocytosis. This process
is a specialized form of clathrin-mediated endocytosis that en-
sures fast and specific retrieval of synaptic vesicle membranes
and is regulated by a multitude of accessory factors (30). HIP1
was originally identified based on its interaction with hunting-
tin (1, 2). Huntingtin is concentrated in presynaptic termini
(31) and interacts with another accessory protein involved in
FIG. 4. Transferrin uptake in COS-7 cells. A, schematic of full-length HIP1 and HIP1 mutants. B, the uptake of Cy3-labeled transferrin into
COS-7 cells (panels v–viii) was analyzed in the presence of various constructs of HIP1. Transfected cells were revealed by immunofluorescence with
an anti-Flag antibody (panels i–iv). Bars, 10 m. C, the graph represents the mean  S.E. from six separate experiments of the percentage of
transferrin uptake for the different constructs. The white and black bars represent non-transfected and transfected cells, respectively.
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endocytosis in neurons, endophilin A3 (SH3GL3) (32). More-
over, huntingtin associates with CCVs (33). The altered inter-
action between mutant huntingtin and HIP1, together with the
direct evidence of the role of HIP1 in endocytosis, leads us to
suggest that mutant huntingtin can significantly influence
HIP1 function and its role in clathrin-mediated endocytosis in
neurons.
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